SGM
ZBIO

Seven Grand Managers’s Zenas BioPharma ZBIO Stock Holding History

Seven Grand Managers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Hold
100,000
– – 0.1% 132
2026
Q1 		$1.96M Buy
+100,000
New +$2.24M 0.13% 118

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Seven Grand Managers's ZBIO Position: Q2 2026 in Review

Seven Grand Managers held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 100,000 shares worth $2.54M. The position accounts for 0.1% of the portfolio, ranked #132.

Seven Grand Managers first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Seven Grand Managers held 100,000 shares of Zenas BioPharma worth $2.54M as of Q2 2026.
  • Seven Grand Managers left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up 0.1% of Seven Grand Managers's portfolio in Q2 2026, its #132 holding.
  • Seven Grand Managers first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.